Canada In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Services), By Technique, By Application, By End Use, By Test Location, By Province, And Segment Forecasts, 2025 - 2030

Canada In Vitro Diagnostics Market Growth & Trends

The Canada in vitro diagnostics market size is expected to reach USD 10.68 billion by 2030, registering a CAGR of 4.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing R&D for the development of the technologically advanced in vitro diagnostics (IVD) systems for laboratories & hospitals to provide efficient, accurate, and error-free diagnosis is expected to fuel market growth. Moreover, the outbreak of COVID-19 disease has increased the growth at a significant rate.

High susceptibility to infections among the geriatric population is anticipated to increase the demand for in vitro diagnostic testing in Canada over the forecast period. The geriatric population is more likely to suffer from COVID-19 due to decreased immune function. According to the government of Canada, there were around 353,000 deaths between March 2020 and mid-May 2021, and people aged 65 and above accounted for around 80% of those deaths.

The country’s leading causes of death include heart disorders, cancer, chronic lower respiratory diseases, cerebrovascular diseases, and diabetes. Heart diseases and cancer accounted for the majority of deaths in Canada. Moreover, death rates from other disorders such as chronic lower respiratory diseases and cirrhosis/chronic liver disease have increased in recent years. The increasing number of cases of diabetes in Canada is anticipated to fuel market growth, with more than 10% of the population currently diagnosed with diabetes.

Moreover, the technological advancements in IVD testing are also expected to boost market growth during the forecast period. For instance, in February 2021, Thermo Fisher Scientific received approval from Health Canada for Applied Biosystems TaqPath COVID-19 HT Kit. Moreover, in June 2020, F. Hoffmann-La Roche Ltd received authorization for the Elecsys Anti-SARS-CoV-2 serology test under Health Canada’s Interim Order to make it available for laboratories and healthcare professionals. The introduction of novel products is expected to drive growth.

Key players in the Canada IVD industry are investing to expand their range of testing by undertaking R&D initiatives for the development of kits that target emerging diseases or by entering into agreements with other key manufacturing companies. In addition, innovative product launch in the market is a result of increasing R&D efforts and partnership programs established by players. For instance, in May 2021, LaunchWorks, a CDMO in molecular diagnostics, and Canadienzyme, a biotech spin-off company by two McGill University scientists, collaborated to produce RT-qPCR Master Mix, RT-qPCR testing reagent. Such initiatives undertaken by key players are expected to propel the market growth in the country.

Canada In Vitro Diagnostics Market Report Highlights

• The reagents segment dominated the market with the largest revenue share of 65.5% in 2024
• The molecular diagnostics segment held the largest market share in 2024, attributed to its crucial role in accurately diagnosing a wide range of diseases.
• The infectious disease segment accounted for the largest market share in 2024, attributed to the high prevalence of infectious diseases and the need for accurate and timely diagnostics.
• The hospital segment held the largest share in 2024, owing to its pivotal role in patient care and diagnostics.
• Ontario's in vitro diagnostics market captured the largest revenue share of 31.1% in 2024, fueled by the advanced healthcare infrastructure of the province and the high prevalence of chronic diseases such as cancer and diabetes.

Please note The report will be delivered in 2-3 business days upon order notification. Show more